Evidence mapPaperPMID 39796486Full record

ReviewNutrients2024

Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease.

Anallely López-Yerena, Victoria de Santisteban Villaplana, Lina Badimon, Gemma Vilahur, Teresa Padro

Abstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anallely López-YerenaInstitut Recerca Sant Pau, Sant Quinti 77-79, 08041 Barcelona, Spain.ORCID 0000-0002-4333-9798
Victoria de Santisteban VillaplanaInstitut Recerca Sant Pau, Sant Quinti 77-79, 08041 Barcelona, Spain.
Lina BadimonInstitut Recerca Sant Pau, Sant Quinti 77-79, 08041 Barcelona, Spain.
Gemma VilahurInstitut Recerca Sant Pau, Sant Quinti 77-79, 08041 Barcelona, Spain.
Teresa PadroInstitut Recerca Sant Pau, Sant Quinti 77-79, 08041 Barcelona, Spain.ORCID 0000-0003-1921-954X

Funding

Fundacio la Marato 202329-10MCIN MCIN/AEI/10.13039/501100011033Spanish Ministry of Economy and Competitiveness of Science and Agencia Estatal de Investigación AEI/10.13039/501100011033-[PID2019-107160RB-I00])Spanish Ministry of Economy and Competitiveness of Science and Agencia Estatal de Investigación PID2021-128891OB-I00
6 · The paper itself

Abstract

Probiotics are gaining recognition as a viable strategy for mitigating cardiovascular risk factors. Specifically, recent studies highlight their potential benefits in managing cholesterol levels, blood pressure, and inflammation, which are critical components in the prevention of cardiovascular diseases (CVD). This comprehensive review aims to elucidate the impact of probiotic consumption on major cardiovascular risk factors, including individuals with hypertension, type II diabetes mellitus, metabolic syndrome, hypercholesterolemia, and in secondary prevention in coronary artery disease. Scientific evidence based on human studies suggests that probiotic consumption is associated with positive effects on anthropometric measures, inflammation markers, blood pressure, glucose metabolism markers, lipid profiles, and endothelial function. However, these findings should be interpreted pragmatically and acknowledge the significant variability in results. This variability may be attributed to factors such as probiotic composition (single strain or multiple strains), the characteristics of the delivery matrix (food, capsules, and sachets), the duration of the intervention, the dosage regimen, and baseline health profiles of the participants. Incorporating probiotics as part of a comprehensive and healthy lifestyle approach can be considered a feasible strategy for both the prevention and management of CVD. However, further research is needed on factors influencing the effect of probiotics, such as: (i) optimal probiotic strain(s), (ii) appropriate dosage, (iii) duration of treatment, (iv) optimal delivery vehicle, and (v) sex-specific differences.

Indexed as

Cardiovascular DiseasesProbioticsDiabetes Mellitus, Type 2Heart Disease Risk FactorsHumansblood pressurefunctional foodsinflammationlipid profile

Identifiers

PMID39796486
PMCPMC11722674

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.